Can Ficicioglu

Dr. Can Ficicioglu

The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
CMChristian R. Marshall
Christian R. Marshall
ANAbdul Noor
Abdul Noor
JVJohn B. Vincent
John B. Vincent
ALAnath C. Lionel
Anath C. Lionel
LFLars Feuk
Lars Feuk
SSStephan Scherer
Stephan Scherer

10 September 2015 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
Barbara K. BurtonBarbara K. Burton
Barbara K. Burton
MBManisha Balwani
Manisha Balwani
FFFrançois Feillet
François Feillet
IBIvo Barić
Ivo Barić
TBT. Andrew Burrow
T. Andrew Burrow
AQAnthony G. Quinn
Anthony G. Quinn
Lysosomal acid lipase is an essential lipid-metabolizing enzyme that breaks down endocytosed lipid particles and regulates lipid metabolism. We conducted a phase 3 trial of enzyme-replacement therapy in children and adults with lysosomal acid lipase deficiency, an underappreciated cause of cirrhosis and severe dyslipidemia.

1 March 2009 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
GAGeorgianne L. Arnold
Georgianne L. Arnold
JHJohan Van Hove
Johan Van Hove
DFDebra Freedenberg
Debra Freedenberg
ASArnold Strauss
Arnold Strauss
NLNicola Longo
Nicola Longo
AFAnnette Feigenbaum
Annette Feigenbaum

18 January 2008 in Human Mutation
Verified
Journal Article
Open access
PDF file
DDD. P. Dimmock
D. P. Dimmock
QZQ. Zhang
Q. Zhang
CDCarlo Dionisi-Vici
Carlo Dionisi-Vici
RCRosalba Carrozzo
Rosalba Carrozzo
JSJ. Shieh
J. Shieh
LWL-J. Wong
L-J. Wong
Published mutations in deoxyguanosine kinase (DGUOK) cause mitochondrial DNA depletion and a clinical phenotype that consists of neonatal liver failure, nystagmus and hypotonia. In this series, we have identified 15 different mutations in the DGUOK gene from 9 kindreds. Among them, 12 have not previously been reported. Nonsense, splice site, or frame‐shift mutations that produce truncated proteins predominate over missense mutations. All patients who harbor null mutations had early onset liver failure and significant neurological disease. These patients have all died before 2‐years of age. Conversely, two patients carrying missense mutations had isolated liver disease and are alive in their 4th year of life without liver transplant. Five subjects were detected by newborn screening, with elevated tyrosine or phenylalanine. Consequently, this disease should be considered if elevated tyrosine is identified by newborn screening. Mitochondrial DNA content was below 10% of controls in liver in all but one case and modestly reduced in blood cells. With this paper a total of 39 different mutations in DGUOK have been identified. The most frequent mutation, c.763_c.766dupGATT, occurs in 8 unrelated kindreds. 70% of mutations occur in only one kindred, suggesting full sequencing of this gene is required for diagnosis. The presentation of one case with apparent viral hepatitis, without neurological disease, suggests that this disease should be considered in patients with infantile liver failure regardless of the presence of neurological features or apparent infectious etiology.

1 February 2018 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
JKJennifer Kwon
Jennifer Kwon
DMDietrich Matern
Dietrich Matern
JKJoanne Kurtzberg
Joanne Kurtzberg
LWLawrence Wrabetz
Lawrence Wrabetz
Michael GelbMichael Gelb
Michael Gelb
Joseph OrsiniJoseph Orsini
Joseph Orsini
Krabbe disease is a rare neurodegenerative genetic disorder caused by deficiency of galactocerebrosidase. Patients with the infantile form of Krabbe disease can be treated at a presymptomatic stage with human stem cell transplantation which improves survival and clinical outcomes. However, without a family history, most cases of infantile Krabbe disease present after onset of symptoms and are ineligible for transplantation. In 2006, New York began screening newborns for Krabbe disease to identify presymptomatic cases. To ensure that those identified with infantile disease received timely treatment, New York public health and medical systems took steps to accurately diagnose and rapidly refer infants for human stem cell transplantation within the first few weeks of life. After 11 years of active screening in New York and the introduction of Krabbe disease newborn screening in other states, new information has been gained which can inform the design of newborn screening programs to improve infantile Krabbe disease outcomes. Recent information relevant to Krabbe disease screening, diagnosis, and treatment were assessed by a diverse group of public health, medical, and advocacy professionals. Outcomes after newborn screening may improve if treatment for infantile disease is initiated before 30 days of life. Newer laboratory screening and diagnostic tools can improve the speed and specificity of diagnosis and help facilitate this early referral. Given the rarity of Krabbe disease, most recommendations were based on case series or expert opinion. This report updates recommendations for Krabbe disease newborn screening to improve the timeliness of diagnosis and treatment of infantile Krabbe disease. In the United States, several states have begun or are considering Krabbe disease newborn screening. These recommendations can guide public health laboratories on methodologies for screening and inform clinicians about the need to promptly diagnose and treat infantile Krabbe disease. The timing of the initial referral after newborn screening, the speed of diagnostic confirmation of infantile disease, and the transplantation center’s experience and ability to rapidly respond to a suspected patient with newly diagnosed infantile Krabbe disease are critical for optimal outcomes.

1 April 2008 in Therapeutics and Clinical Risk Management
Verified
Journal Article
Open access
PDF file
Can FiciciogluCan Ficicioglu
Can Ficicioglu
Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articlesor submit your research for publishing